Sections
Title | Starting Page | Number of Pages |
---|
Table of Contents | 2 | 10 |
List of Tables | 10 | 1 |
List of Figures | 11 | 1 |
Introduction | 12 | 1 |
Global Markets Direct Report Coverage | 12 | 1 |
Psoriatic Arthritis Overview | 13 | 1 |
Therapeutics Development | 14 | 2 |
Pipeline Products for Psoriatic Arthritis Overview | 14 | 1 |
Pipeline Products for Psoriatic Arthritis Comparative Analysis | 15 | 1 |
Psoriatic Arthritis Therapeutics under Development by Companies | 16 | 3 |
Psoriatic Arthritis Pipeline Products Glance | 19 | 4 |
Late Stage Products | 19 | 1 |
Clinical Stage Products | 20 | 1 |
Early Stage Products | 21 | 1 |
Unknown Stage Products | 22 | 1 |
Psoriatic Arthritis Products under Development by Companies | 23 | 4 |
Psoriatic Arthritis Companies Involved in Therapeutics Development | 27 | 33 |
3SBio Inc. | 27 | 1 |
AbbVie Inc | 28 | 1 |
AbGenomics International, Inc. | 29 | 1 |
Alteogen Inc. | 30 | 1 |
Amgen Inc. | 31 | 1 |
Biocon Limited | 32 | 1 |
Bionovis SA | 33 | 1 |
Bristol-Myers Squibb Company | 34 | 1 |
Celgene Corporation | 35 | 1 |
Coherus BioSciences, Inc. | 36 | 1 |
Eli Lilly and Company | 37 | 1 |
Forward Pharma A/S | 38 | 1 |
Genor BioPharma Co Ltd | 39 | 1 |
Innovent Biologics, Inc. | 40 | 1 |
Johnson &Johnson | 41 | 1 |
Kadmon Corporation, LLC | 42 | 1 |
KPI Therapeutics, Inc. | 43 | 1 |
Momenta Pharmaceuticals, Inc. | 44 | 1 |
Morphotek, Inc. | 45 | 1 |
Mycenax Biotech Inc. | 46 | 1 |
NeuClone Pty Ltd | 47 | 1 |
Novo Nordisk A/S | 48 | 1 |
Oncobiologics, Inc. | 49 | 1 |
Pfizer Inc. | 50 | 1 |
Prothena Corporation Plc | 51 | 1 |
Reliance Life Sciences Pvt. Ltd. | 52 | 1 |
Sandoz International GmbH | 53 | 1 |
Therapeutic Proteins International, LLC | 54 | 1 |
UCB SA | 55 | 1 |
Valeant Pharmaceuticals International, Inc. | 56 | 1 |
Vitae Pharmaceuticals, Inc. | 57 | 1 |
Vitaeris Inc | 58 | 1 |
Xbrane Biopharma AB | 59 | 1 |
Psoriatic Arthritis Therapeutics Assessment | 60 | 11 |
Assessment by Monotherapy Products | 60 | 1 |
Assessment by Target | 61 | 3 |
Assessment by Mechanism of Action | 64 | 3 |
Assessment by Route of Administration | 67 | 2 |
Assessment by Molecule Type | 69 | 2 |
Drug Profiles | 71 | 139 |
abatacept Drug Profile | 71 | 5 |
AbGn-168H Drug Profile | 76 | 2 |
ABT-122 Drug Profile | 78 | 2 |
adalimumab biosimilar Drug Profile | 80 | 2 |
adalimumab biosimilar Drug Profile | 82 | 1 |
adalimumab biosimilar Drug Profile | 83 | 1 |
adalimumab biosimilar Drug Profile | 84 | 1 |
adalimumab biosimilar Drug Profile | 85 | 1 |
adalimumab biosimilar Drug Profile | 86 | 1 |
adalimumab biosimilar Drug Profile | 87 | 2 |
adalimumab biosimilar Drug Profile | 89 | 2 |
adalimumab biosimilar Drug Profile | 91 | 1 |
adalimumab biosimilar Drug Profile | 92 | 1 |
adalimumab biosimilar Drug Profile | 93 | 1 |
adalimumab biosimilar Drug Profile | 94 | 1 |
adalimumab biosimilar Drug Profile | 95 | 1 |
adalimumab biosimilar Drug Profile | 96 | 1 |
apremilast Drug Profile | 97 | 11 |
apremilast Drug Profile | 108 | 1 |
bimekizumab Drug Profile | 109 | 2 |
certolizumab pegol biosimilar Drug Profile | 111 | 1 |
clazakizumab Drug Profile | 112 | 4 |
dalazatide Drug Profile | 116 | 5 |
dimethyl fumarate Drug Profile | 121 | 2 |
DNX-114 Drug Profile | 123 | 1 |
DNX-514 Drug Profile | 124 | 1 |
Drug to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Drug Profile | 125 | 1 |
etanercept Drug Profile | 126 | 2 |
etanercept biosimilar Drug Profile | 128 | 1 |
etanercept biosimilar Drug Profile | 129 | 1 |
etanercept biosimilar Drug Profile | 130 | 1 |
etanercept biosimilar Drug Profile | 131 | 1 |
etanercept biosimilar Drug Profile | 132 | 3 |
etanercept biosimilar Drug Profile | 135 | 1 |
etanercept biosimilar Drug Profile | 136 | 2 |
golimumab Drug Profile | 138 | 8 |
golimumab biosimilar Drug Profile | 146 | 1 |
golimumab biosimilar Drug Profile | 147 | 1 |
guselkumab Drug Profile | 148 | 4 |
infliximab biosimilar Drug Profile | 152 | 1 |
infliximab biosimilar Drug Profile | 153 | 1 |
infliximab biosimilar Drug Profile | 154 | 3 |
infliximab biosimilar Drug Profile | 157 | 1 |
infliximab biosimilar Drug Profile | 158 | 3 |
infliximab biosimilar Drug Profile | 161 | 1 |
infliximab biosimilar Drug Profile | 162 | 1 |
INV-17 Drug Profile | 163 | 1 |
itolizumab Drug Profile | 164 | 2 |
ixekizumab Drug Profile | 166 | 6 |
KANAb-071 Drug Profile | 172 | 1 |
KD-025 Drug Profile | 173 | 4 |
liraglutide Drug Profile | 177 | 7 |
PRX-003 Drug Profile | 184 | 2 |
risankizumab Drug Profile | 186 | 3 |
tofacitinib citrate Drug Profile | 189 | 13 |
upadacitinib tartrate Drug Profile | 202 | 2 |
ustekinumab biosimilar Drug Profile | 204 | 1 |
ustekinumab biosimilar Drug Profile | 205 | 1 |
VALBRO-03 Drug Profile | 206 | 1 |
VTP-43742 Drug Profile | 207 | 3 |
Psoriatic Arthritis Dormant Projects | 210 | 2 |
Psoriatic Arthritis Discontinued Products | 212 | 1 |
Psoriatic Arthritis Product Development Milestones | 213 | 17 |
Featured News &Press Releases | 213 | 1 |
Nov 07, 2016: Amgen To Present Data On Etanercept At ACR/ARHP 2016 Annual Meeting | 213 | 1 |
Nov 07, 2016: Pfizer to Present Additional Research For XELJANZ (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis | 214 | 2 |
Nov 03, 2016: Janssen To Present Data on Guselkumab (Anti-IL23 mAb) At The 2016 American College Of Rheumatology Meeting | 216 | 2 |
Nov 03, 2016: Lilly Presents Data on ixekizumab at 2016 American College of Rheumatology Annual Meeting | 218 | 1 |
Oct 18, 2016: Catalent To Provide Fill &Finish Services For Commercial Supply Of Samsung Bioepis Biosimilar Therapy | 218 | 1 |
Sep 29, 2016: Prothena Outlines Phase 2 Development Strategy for PRX003 | 219 | 1 |
Sep 28, 2016: Oral OTEZLA (apremilast) Long-Term Safety Data Presented at EADV Congress in Both Psoriasis and Psoriatic Arthritis | 220 | 2 |
Aug 30, 2016: FDA approves Erelzi, a biosimilar to Enbrel | 222 | 1 |
Jul 17, 2016: SB5, An Adalimumab Biosimilar Referencing Humira, Accepted for Review by European Medicines Agency | 223 | 1 |
Jun 14, 2016: SIMPONI (golimumab) shows long-term treatment persistence and improved quality of life in patients with rheumatic diseases | 223 | 2 |
Jun 10, 2016: UCB s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis | 225 | 1 |
Jun 09, 2016: Prothena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases | 226 | 1 |
Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016) | 226 | 1 |
Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology | 227 | 1 |
Jun 07, 2016: Pfizer Announces Positive Top-Line Results From Second Phase 3 Trial Of Oral XELJANZ (Tofacitinib Citrate) In Adults With Psoriatic Arthritis | 228 | 2 |
Appendix | 230 | 2 |
Methodology | 230 | 1 |
Coverage | 230 | 1 |
Secondary Research | 230 | 1 |
Primary Research | 230 | 1 |
Expert Panel Validation | 230 | 1 |
Contact Us | 230 | 1 |
Disclaimer | 231 | 1 |